ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.

Article - 14/01/2021

Newly discovered RNA as growth driver in liver cancer

Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

SolidCAR-T project - 15/03/2022

Modular ‘mini-factories’ for decentralised production of CAR T cells

Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

Making existing cancer therapy more efficient while significantly reducing the side effects on healthy tissue - this is the aim of a project at Aalen University. It is being funded with one million euros from the Carl Zeiss Foundation. The biophysicist and his team are developing innovative nanoparticles made of gold. The particles use radiotherapy and chemotherapy simultaneously and kill the cancer cells in a targeted manner.

A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response.

Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.

With its Proof of Concept grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now received this coveted funding for the second time.

Stem cell research - 14/03/2024

Using organoids to gain a better clinical understanding of pancreatic cancer

Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.

Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.

The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.

In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

Cytolytics GmbH - 14/02/2023

Bioinformatics meets medical diagnostics and drug development

The start-up company Cytolytics from Tübingen has developed a robust and user-friendly software platform that uses machine learning for the automated analysis of cells. This is beneficial in areas such as cancer diagnostics and the development of new pharmaceutically active substances.

Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.

A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.

CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.